TG Therapeutics' (TGTX) Treatment for Chronic Lymphocytic Leukemia Granted Orphan Status by FDA
- AT&T (T) Agrees to Acquire Time Warner (TWX) for More than $80 Billion - WSJ
- Top 10 News for 10/17 - 10/21: Merger Rumors Abound; CEOs Depart; Tesla Kicks Autopilot Up A Notch
- Wall Street ends little changed; Microsoft hits record
- AT&T (T) in Advanced Talks to Acquire Time Warner (TWX) - DJ
- Rockwell Automation (ROK) Said to Attract Takeover Interest from Schneider Electric - Source
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
TG Therapeutics' (NASDAQ: TGTX) treatment for chronic lymphocytic leukemia was granted orphan status by the FDA. The generic name is phosphoinositide-3-kinase delta inhibitor.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TG Therapeutics (TGTX) Launches TGR-1202 Phase 12 in r/r Lymphoma
- Viveve Medical (VIVE) Files Patent Infringement Lawsuit Against Thermi in Texas
- Vascular Solutions' (VASC) Fluent Inflation Device Receives FDA 510(k) Clearance
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!